LENZILUMAB EFFICACY AND SAFETY IN NEWLY HOSPITALIZED COVID-19 SUBJECTS: RESULTS FROM THE LIVE-AIR PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL
Zelalem Temesgen, Charles D. Burger, Jason Baker, Christopher Polk, Claudia Libertin, Colleen Kelley, Vincent C. Marconi, Robert Orenstein, Cameron Durrant, Dale Chappell, Omar Ahmed, Gabrielle Chappell, Andrew D. Badley
doi: https://doi.org/10.1101/2021.05.01.21256470
Zelalem Temesgen
1Mayo Clinic, Division of Infectious Disease, Rochester, MN
Charles D. Burger
2Mayo Clinic, Division of Pulmonary, Allergy and Sleep Medicine, Jacksonville, FL
Jason Baker
3Hennepin Healthcare Research Institute, Minneapolis, MN
Christopher Polk
4Atrium Health, Charlotte, NC
Claudia Libertin
5Mayo Clinic, Division of Infectious Disease, Jacksonville, FL
Colleen Kelley
6Emory University School of Medicine, Division of Infectious Diseases; Special Immunology Service Grady Memorial Hospital, Atlanta, GA
Vincent C. Marconi
7Emory University School of Medicine, Rollins School of Public Health, and Emory Vaccine Center, Division of Infectious Diseases, Atlanta, GA
Robert Orenstein
8Mayo Clinic, Division of Infectious Disease, Scottsdale, AZ
Cameron Durrant
9Humanigen, Inc., Burlingame, CA
Dale Chappell
9Humanigen, Inc., Burlingame, CA
Omar Ahmed
9Humanigen, Inc., Burlingame, CA
Gabrielle Chappell
9Humanigen, Inc., Burlingame, CA
Andrew D. Badley
10Mayo Clinic, Division of Infectious Disease and Department of Molecular Medicine, Rochester, MN
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Posted May 05, 2021.
LENZILUMAB EFFICACY AND SAFETY IN NEWLY HOSPITALIZED COVID-19 SUBJECTS: RESULTS FROM THE LIVE-AIR PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL
Zelalem Temesgen, Charles D. Burger, Jason Baker, Christopher Polk, Claudia Libertin, Colleen Kelley, Vincent C. Marconi, Robert Orenstein, Cameron Durrant, Dale Chappell, Omar Ahmed, Gabrielle Chappell, Andrew D. Badley
medRxiv 2021.05.01.21256470; doi: https://doi.org/10.1101/2021.05.01.21256470
LENZILUMAB EFFICACY AND SAFETY IN NEWLY HOSPITALIZED COVID-19 SUBJECTS: RESULTS FROM THE LIVE-AIR PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL
Zelalem Temesgen, Charles D. Burger, Jason Baker, Christopher Polk, Claudia Libertin, Colleen Kelley, Vincent C. Marconi, Robert Orenstein, Cameron Durrant, Dale Chappell, Omar Ahmed, Gabrielle Chappell, Andrew D. Badley
medRxiv 2021.05.01.21256470; doi: https://doi.org/10.1101/2021.05.01.21256470
Subject Area
Subject Areas
- Addiction Medicine (399)
- Allergy and Immunology (708)
- Anesthesia (200)
- Cardiovascular Medicine (2918)
- Dermatology (249)
- Emergency Medicine (438)
- Epidemiology (12711)
- Forensic Medicine (12)
- Gastroenterology (827)
- Genetic and Genomic Medicine (4567)
- Geriatric Medicine (415)
- Health Economics (726)
- Health Informatics (2913)
- Health Policy (1068)
- Hematology (386)
- HIV/AIDS (922)
- Medical Education (422)
- Medical Ethics (115)
- Nephrology (467)
- Neurology (4335)
- Nursing (234)
- Nutrition (636)
- Oncology (2261)
- Ophthalmology (643)
- Orthopedics (258)
- Otolaryngology (324)
- Pain Medicine (278)
- Palliative Medicine (83)
- Pathology (499)
- Pediatrics (1196)
- Primary Care Research (494)
- Public and Global Health (6916)
- Radiology and Imaging (1524)
- Respiratory Medicine (915)
- Rheumatology (436)
- Sports Medicine (383)
- Surgery (486)
- Toxicology (60)
- Transplantation (210)
- Urology (178)